Celsion Corp (CLSN) 2.41 $CLSN
Celsion Corporation and myTomorrows Partner to Introduce ThermoDox(R) Early Access Program in Europe for Patients with Recurrent Chest Wall Breast Cancer
PR Newswire Europe - Tue Jan 20, 7:01AM CST
Celsion Corporation , a fully-integrated oncology company focused on the development of a portfolio of innovative cancer treatments, today announced that it has signed a license and distribution agreement with myTomorrows to implement an Early Access Program for ThermoDox(R), its proprietary heat-activated liposomal encapsulation of doxorubicin, in all countries of the European Union (EU) territory plus Switzerland for the treatment of patients with recurrent chest wall (RCW) breast cancer.
CLSN: 2.41 (+0.09)
Celsion Corporation and myTomorrows Partner to Introduce ThermoDox® Early Access Program in Europe for Patients with Recurrent Chest Wall Breast Cancer
PR Newswire - Tue Jan 20, 7:00AM CST
Celsion Corporation (NASDAQ:CLSN), a fully-integrated oncology company focused on the development of a portfolio of innovative cancer treatments, today announced that it has signed a license and distribution agreement with myTomorrows to implement an Early Access Program for ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin, in all countries of the European Union (EU) territory plus Switzerland for the treatment of patients with recurrent chest wall (RCW) breast cancer.
CLSN: 2.41 (+0.09)
The Market for Personalized Gene Therapy Treatments for Cancer
M2 - Fri Jan 16, 8:59AM CST
Research and Markets (http://www.researchandmarkets.com/research/9ddkrc/the_market_for) has announced the addition of the "The Market for Personalized Gene Therapy Treatments for Cancer" report to their offering. This report, The Market for Personalized Gene Therapy Treatments For Cancer provides an exhaustive review of the market potential for relatively new approach in cancer research. It involves modification of genes instead of using a surgical method or chemical drug product. Essentially, gene therapies replace an abnormal gene with a normal gene, or changes the response of a gene (turn on or off). Not all of the approaches to gene therapy are the same, and different cancers appear to respond better to different therapies. Several gene therapy technologies have the ability to work in combination with other treatment options to enhance the effectiveness of a therapeutic regimen. Gene therapy is also designed to target specific cells making treatment much less damaging to healthy cells. This report discusses those treatments and estimates market size and market potential for personalized medicine using gene therapy. In addition the report provides: - Overview of Gene Therapy - Overall Market Size and Forecast - Cancer Therapeutic Market Totals - Discussion of Somati vs. Germ Line Gene Therapy - R&D Activities - Company Profiles Key Topics Covered: - Executive Summary - Gene Therapy Overview - Cancer and Gene Therapy - Gene Therapy Outlook in Bladder Cancer - Gene Therapy Outlook in Brain Cancer - Gene Therapy Outlook in Breast Cancer - Gene Therapy Outlook in Colorectal Cancer - Gene Therapy Outlook in Head & Neck Cancer - Gene Therapy Outlook in Leukemia - Gene Therapy Outlook in Liver Cancer - Gene Therapy Outlook in Lung Cancer - Gene Therapy Outlook in Lymphoma - Gene Therapy Outlook in Melanoma - Gene Therapy Outlook in Ovarian Cancer - Gene Therapy Outlook in Pancreatic Cancer - Gene Therapy Outlook in Prostate Cancer - Gene Therapy and Other Cancers - Gene Therapy in Cancer Market Summary and Outlook - Industry Participants and Contributors Companies Mentioned - Advantagene, Inc. - Amgen, Inc. - Bellicum Pharmaceuticals, Inc. - BioCancell Ltd. - Blubird Bio - Celgene - Celsion Corporation - Chengdu Shi Endor Biological Engineering Technology Co., Ltd. - Cold Genesys, Inc. - Genprex, Inc. - MaxiVax SA - Momotaro-Gene, Inc. - MultiVir, Inc. - OncoSec Medical, Inc. - Sevion Therapeutics, Inc. - SynerGene Therapeutics, Inc. - Takara Bio, Inc. - Tocagen, Inc. - VBL Therapeutics Ltd. - Ziopharm Oncology, Inc. - daptimmune Ltd. For more information visit http://www.researchandmarkets.com/research/9d...market_for
CLSN: 2.41 (+0.09), BLCM: 20.00 (-0.81), AMGN: 153.48 (+0.30), CELGZ: 3.17 (-0.04)
ORYZON Appoints Greg Weaver as Global Chief Financial Officer
PR Newswire - Mon Jan 12, 2:00AM CST
Oryzon Genomics SA, a clinical stage biopharmaceutical company developing therapeutics in oncology and CNS diseases based on its proprietary epigenetics technology platform, today announced the appointment of Gregory L. Weaver as Executive Vice President and Chief Financial Officer, effective January 12, 2015. Weaver brings more than 30 years of experience to Oryzon, including extensive financial and operational experience with publicly- and privately-held biotechnology companies. Weaver will report directly to Carlos Buesa, President and Chief Executive Officer of Oryzon, and will be based at Oryzon's U.S. headquarters, located at 245 First Street in Cambridge, MA.
ATOS: 1.67 (+0.11), CLSN: 2.41 (+0.09), EGLT: 10.60 (+0.58), FCSC: 4.75 (+0.50)
Celsion Submits Study Protocol for Oncology Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 07, 3:20PM CST
Celsion Corporation (CLSN) announced that it has submitted a phase I study protocol for GEN-1 to the FDA.
CLSN: 2.41 (+0.09), INCY: 75.94 (+0.28), AZN: 69.96 (+0.20), AFFX: 11.45 (+0.02)
Celsion Corporation Submits DNA-based Immunotherapy Clinical Protocol to the FDA as Part of a First Line Treatment for Ovarian Cancer
PR Newswire - Tue Jan 06, 7:00AM CST
Celsion Corporation (Celsion) (NASDAQ:CLSN), a fully-integrated oncology company focused on the development of a portfolio of innovative cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies for the treatment of cancer and other difficult-to-treat diseases, today announced the submission of its Phase I clinical trial protocol to the U.S. Food and Drug Administration (FDA) for GEN-1, the Company's DNA-based immunotherapy for the localized treatment of cancer. The protocol, developed with guidance from the Company's Medical Advisory Board, is designed to establish a safe dose and biological activity of GEN-1 in newly diagnosed ovarian cancer patients who will be undergoing neoadjuvant chemotherapy. GEN-1 has demonstrated encouraging safety and efficacy data in a previous Phase I monotherapy trial in patients with peritoneally metastasized ovarian cancer, and is currently being evaluated in a Phase Ib trial in combination with PEGylated doxorubicin in patients with platinum-resistant ovarian cancer.
CLSN: 2.41 (+0.09)
Insider Trading Alert - GWRE, CLSN And ADI Traded By Insiders
at The Street - Tue Dec 23, 1:30PM CST
Stocks with insider trader activity include GWRE, CLSN and ADI
CLSN: 2.41 (+0.09), GWRE: 54.81 (+0.42), ADI: 57.05 (+0.33)
Celsion's Prospects For A Significant Upside Just Got A Lot Better
Clinically Sound Investor - at Seeking Alpha - Thu Nov 20, 11:12AM CST
CLSN: 2.41 (+0.09)
Celsion net loss worsens in Q3
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 11:18AM CST
CLSN: 2.41 (+0.09)
Celsion's (CLSN) CEO Michael Tardugno on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 11, 8:54PM CST
CLSN: 2.41 (+0.09)
Celsion (CLSN) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Tue Nov 11, 3:25PM CST
CLSN: 2.41 (+0.09)
Celsion misses by $0.03, revenue in-line
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 11:58AM CST
CLSN: 2.41 (+0.09)
Celsion Corporation Reports Third Quarter 2014 Financial Results
PR Newswire - Tue Nov 11, 7:00AM CST
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced financial results for the third quarter ended September 30, 2014. The Company also provided an update on its development programs for ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin, and two newly acquired technology platforms, TheraPlas(TM) and TheraSilence(TM), in immunotherapy and RNA delivery.
CLSN: 2.41 (+0.09)
Celsion Corporation Receives VHP Approval to Initiate OPTIMA Study in Europe
PR Newswire - Wed Nov 05, 7:00AM CST
Celsion Corporation (NASDAQ: CLSN) announced today that the Phase III OPTIMA Study was approved via Europe's centralized Voluntary Harmonization Procedure (VHP). The approval allows Celsion to conduct the OPTIMA Study, its Phase III trial of ThermoDox® in primary liver cancer, also known as hepatocellular carcinoma (HCC), in Europe. In addition to Italy, the OPTIMA Study will now include sites in Spain and Germany. The OPTIMA Study is the Company's global pivotal, double-blind, placebo-controlled trial, evaluating ThermoDox®, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin, in combination with radiofrequency ablation standardized to 45 minutes (sRFA) versus sRFA alone to treat patients with non-resectable HCC lesions. HCC is the largest unmet medical need remaining in oncology with annual incidence over 750,000 and non-resectable RFA candidates representing some 30% of the newly diagnosed patients. The OPTIMA Study is actively recruiting and enrolling patients at sites in the United States, Hong Kong, South Korea, Malaysia and Thailand. Additional clinical sites in Canada, Taiwan, and the Philippines are expected to begin recruitment before the end of the year with China FDA (CFDA) regulatory approval to follow in early 2015.
CLSN: 2.41 (+0.09)
Celsion reports November 11
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 10:50AM CST
CLSN: 2.41 (+0.09)
Celsion Corporation to Hold Third Quarter 2014 Financial Results Conference Call on Tuesday, November 11, 2014
PR Newswire - Tue Nov 04, 7:00AM CST
Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss its third quarter 2014 financial results at 4:30 p.m. ET on Tuesday, November 11, 2014. To participate in the call, interested parties may dial 1-888-430-8709 (Toll-Free/North America) or 1-719-457-1512 (International/Toll) and ask for the Celsion Corporation Third Quarter 2014 Conference Call (Conference Code: 3981708) to register ten minutes before the call is scheduled to begin. The call will also be broadcast live on the internet at http://www.celsion.com.
CLSN: 2.41 (+0.09)
Celsion Presents Preclinical Data for its TheraSilence(TM) Platform at the miRNA World Conference Workshop on miRNA Delivery
PR Newswire - Wed Oct 29, 7:00AM CDT
Celsion Corporation (NASDAQ: CLSN) today announced the presentation of data related to TheraSilence(TM), the Company's lung-specific RNA delivery technology, at the miRNA World Conference Workshop on miRNA Delivery in Boston, MA. The data was presented by Dr. Khursheed Anwer, Celsion's Executive Vice President and Chief Scientific Officer, during a panel presentation, and highlighted formulation characteristics of the TheraSilence delivery platform, preclinical proof-of concept data and data supportive of GEN-2 (formerly referred to as EGEN-002), Celsion's RNA interference (RNAi) therapeutic for the treatment of lung cancer. Celsion acquired the TheraSilence platform and GEN-2 through its acquisition of EGEN, Inc. in June 2014.
CLSN: 2.41 (+0.09)
Celsion Announces Appointment of Michael H. Tardugno to Executive Chairman of the Board of Directors
PR Newswire - Tue Oct 07, 4:00PM CDT
Celsion Corporation (NASDAQ: CLSN) announced that the Board of Directors has appointed Michael H. Tardugno, the Company's President and CEO, to the additional position of Executive Chairman of the Board. Mr. Tardugno's appointment is consistent with the Board's previously established succession plan and follows the passing of Max E. Link, Ph.D. which was announced earlier today. At the direction of Mr. Tardugno, the Nominating Committee of the Board of Directors has begun the process to identify qualified candidates to fill the vacancy on the Company's Board.
CLSN: 2.41 (+0.09), ABT: 46.09 (+0.87), BMY: 60.04 (+0.56)
Celsion Announces The Unexpected Passing of Max E. Link, Ph.D., Chairman of the Board
PR Newswire - Tue Oct 07, 3:35PM CDT
Celsion Corporation (NASDAQ: CLSN) is saddened to announce the passing of Max E. Link, Ph.D., a Director and the Chairman of the Board of Directors of the Company. Dr. Link passed away unexpectedly at the age of 74.
CLSN: 2.41 (+0.09)
INVESTOR ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Celsion Corp. Regarding Possible Breaches of Fiduciary Duty
PR Newswire - Wed Sep 17, 1:18PM CDT
Levi & Korsinsky, LLP is investigating Celsion Corp. (NasdaqCM: CLSN) in connection with possible claims of breaches of fiduciary duty by the board of directors of the Company.
CLSN: 2.41 (+0.09)
Celsion Corporation and myTomorrows Partner to Introduce ThermoDox(R) Early Access Program in Europe for Patients with Recurrent Chest Wall Breast Cancer
PR Newswire Europe - Tue Jan 20, 7:01AM CST
Celsion Corporation , a fully-integrated oncology company focused on the development of a portfolio of innovative cancer treatments, today announced that it has signed a license and distribution agreement with myTomorrows to implement an Early Access Program for ThermoDox(R), its proprietary heat-activated liposomal encapsulation of doxorubicin, in all countries of the European Union (EU) territory plus Switzerland for the treatment of patients with recurrent chest wall (RCW) breast cancer.
CLSN: 2.41 (+0.09)
Celsion Corporation and myTomorrows Partner to Introduce ThermoDox® Early Access Program in Europe for Patients with Recurrent Chest Wall Breast Cancer
PR Newswire - Tue Jan 20, 7:00AM CST
Celsion Corporation (NASDAQ:CLSN), a fully-integrated oncology company focused on the development of a portfolio of innovative cancer treatments, today announced that it has signed a license and distribution agreement with myTomorrows to implement an Early Access Program for ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin, in all countries of the European Union (EU) territory plus Switzerland for the treatment of patients with recurrent chest wall (RCW) breast cancer.
CLSN: 2.41 (+0.09)
The Market for Personalized Gene Therapy Treatments for Cancer
M2 - Fri Jan 16, 8:59AM CST
Research and Markets (http://www.researchandmarkets.com/research/9ddkrc/the_market_for) has announced the addition of the "The Market for Personalized Gene Therapy Treatments for Cancer" report to their offering. This report, The Market for Personalized Gene Therapy Treatments For Cancer provides an exhaustive review of the market potential for relatively new approach in cancer research. It involves modification of genes instead of using a surgical method or chemical drug product. Essentially, gene therapies replace an abnormal gene with a normal gene, or changes the response of a gene (turn on or off). Not all of the approaches to gene therapy are the same, and different cancers appear to respond better to different therapies. Several gene therapy technologies have the ability to work in combination with other treatment options to enhance the effectiveness of a therapeutic regimen. Gene therapy is also designed to target specific cells making treatment much less damaging to healthy cells. This report discusses those treatments and estimates market size and market potential for personalized medicine using gene therapy. In addition the report provides: - Overview of Gene Therapy - Overall Market Size and Forecast - Cancer Therapeutic Market Totals - Discussion of Somati vs. Germ Line Gene Therapy - R&D Activities - Company Profiles Key Topics Covered: - Executive Summary - Gene Therapy Overview - Cancer and Gene Therapy - Gene Therapy Outlook in Bladder Cancer - Gene Therapy Outlook in Brain Cancer - Gene Therapy Outlook in Breast Cancer - Gene Therapy Outlook in Colorectal Cancer - Gene Therapy Outlook in Head & Neck Cancer - Gene Therapy Outlook in Leukemia - Gene Therapy Outlook in Liver Cancer - Gene Therapy Outlook in Lung Cancer - Gene Therapy Outlook in Lymphoma - Gene Therapy Outlook in Melanoma - Gene Therapy Outlook in Ovarian Cancer - Gene Therapy Outlook in Pancreatic Cancer - Gene Therapy Outlook in Prostate Cancer - Gene Therapy and Other Cancers - Gene Therapy in Cancer Market Summary and Outlook - Industry Participants and Contributors Companies Mentioned - Advantagene, Inc. - Amgen, Inc. - Bellicum Pharmaceuticals, Inc. - BioCancell Ltd. - Blubird Bio - Celgene - Celsion Corporation - Chengdu Shi Endor Biological Engineering Technology Co., Ltd. - Cold Genesys, Inc. - Genprex, Inc. - MaxiVax SA - Momotaro-Gene, Inc. - MultiVir, Inc. - OncoSec Medical, Inc. - Sevion Therapeutics, Inc. - SynerGene Therapeutics, Inc. - Takara Bio, Inc. - Tocagen, Inc. - VBL Therapeutics Ltd. - Ziopharm Oncology, Inc. - daptimmune Ltd. For more information visit http://www.researchandmarkets.com/research/9d...market_for
CLSN: 2.41 (+0.09), BLCM: 20.00 (-0.81), AMGN: 153.48 (+0.30), CELGZ: 3.17 (-0.04)
ORYZON Appoints Greg Weaver as Global Chief Financial Officer
PR Newswire - Mon Jan 12, 2:00AM CST
Oryzon Genomics SA, a clinical stage biopharmaceutical company developing therapeutics in oncology and CNS diseases based on its proprietary epigenetics technology platform, today announced the appointment of Gregory L. Weaver as Executive Vice President and Chief Financial Officer, effective January 12, 2015. Weaver brings more than 30 years of experience to Oryzon, including extensive financial and operational experience with publicly- and privately-held biotechnology companies. Weaver will report directly to Carlos Buesa, President and Chief Executive Officer of Oryzon, and will be based at Oryzon's U.S. headquarters, located at 245 First Street in Cambridge, MA.
ATOS: 1.67 (+0.11), CLSN: 2.41 (+0.09), EGLT: 10.60 (+0.58), FCSC: 4.75 (+0.50)
Celsion Submits Study Protocol for Oncology Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 07, 3:20PM CST
Celsion Corporation (CLSN) announced that it has submitted a phase I study protocol for GEN-1 to the FDA.
CLSN: 2.41 (+0.09), INCY: 75.94 (+0.28), AZN: 69.96 (+0.20), AFFX: 11.45 (+0.02)
Celsion Corporation Submits DNA-based Immunotherapy Clinical Protocol to the FDA as Part of a First Line Treatment for Ovarian Cancer
PR Newswire - Tue Jan 06, 7:00AM CST
Celsion Corporation (Celsion) (NASDAQ:CLSN), a fully-integrated oncology company focused on the development of a portfolio of innovative cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies for the treatment of cancer and other difficult-to-treat diseases, today announced the submission of its Phase I clinical trial protocol to the U.S. Food and Drug Administration (FDA) for GEN-1, the Company's DNA-based immunotherapy for the localized treatment of cancer. The protocol, developed with guidance from the Company's Medical Advisory Board, is designed to establish a safe dose and biological activity of GEN-1 in newly diagnosed ovarian cancer patients who will be undergoing neoadjuvant chemotherapy. GEN-1 has demonstrated encouraging safety and efficacy data in a previous Phase I monotherapy trial in patients with peritoneally metastasized ovarian cancer, and is currently being evaluated in a Phase Ib trial in combination with PEGylated doxorubicin in patients with platinum-resistant ovarian cancer.
CLSN: 2.41 (+0.09)
Insider Trading Alert - GWRE, CLSN And ADI Traded By Insiders
at The Street - Tue Dec 23, 1:30PM CST
Stocks with insider trader activity include GWRE, CLSN and ADI
CLSN: 2.41 (+0.09), GWRE: 54.81 (+0.42), ADI: 57.05 (+0.33)
Celsion's Prospects For A Significant Upside Just Got A Lot Better
Clinically Sound Investor - at Seeking Alpha - Thu Nov 20, 11:12AM CST
CLSN: 2.41 (+0.09)
Celsion net loss worsens in Q3
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 11:18AM CST
CLSN: 2.41 (+0.09)
Celsion's (CLSN) CEO Michael Tardugno on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 11, 8:54PM CST
CLSN: 2.41 (+0.09)
Celsion (CLSN) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Tue Nov 11, 3:25PM CST
CLSN: 2.41 (+0.09)
Celsion misses by $0.03, revenue in-line
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 11:58AM CST
CLSN: 2.41 (+0.09)
Celsion Corporation Reports Third Quarter 2014 Financial Results
PR Newswire - Tue Nov 11, 7:00AM CST
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced financial results for the third quarter ended September 30, 2014. The Company also provided an update on its development programs for ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin, and two newly acquired technology platforms, TheraPlas(TM) and TheraSilence(TM), in immunotherapy and RNA delivery.
CLSN: 2.41 (+0.09)
Celsion Corporation Receives VHP Approval to Initiate OPTIMA Study in Europe
PR Newswire - Wed Nov 05, 7:00AM CST
Celsion Corporation (NASDAQ: CLSN) announced today that the Phase III OPTIMA Study was approved via Europe's centralized Voluntary Harmonization Procedure (VHP). The approval allows Celsion to conduct the OPTIMA Study, its Phase III trial of ThermoDox® in primary liver cancer, also known as hepatocellular carcinoma (HCC), in Europe. In addition to Italy, the OPTIMA Study will now include sites in Spain and Germany. The OPTIMA Study is the Company's global pivotal, double-blind, placebo-controlled trial, evaluating ThermoDox®, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin, in combination with radiofrequency ablation standardized to 45 minutes (sRFA) versus sRFA alone to treat patients with non-resectable HCC lesions. HCC is the largest unmet medical need remaining in oncology with annual incidence over 750,000 and non-resectable RFA candidates representing some 30% of the newly diagnosed patients. The OPTIMA Study is actively recruiting and enrolling patients at sites in the United States, Hong Kong, South Korea, Malaysia and Thailand. Additional clinical sites in Canada, Taiwan, and the Philippines are expected to begin recruitment before the end of the year with China FDA (CFDA) regulatory approval to follow in early 2015.
CLSN: 2.41 (+0.09)
Celsion reports November 11
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 10:50AM CST
CLSN: 2.41 (+0.09)
Celsion Corporation to Hold Third Quarter 2014 Financial Results Conference Call on Tuesday, November 11, 2014
PR Newswire - Tue Nov 04, 7:00AM CST
Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss its third quarter 2014 financial results at 4:30 p.m. ET on Tuesday, November 11, 2014. To participate in the call, interested parties may dial 1-888-430-8709 (Toll-Free/North America) or 1-719-457-1512 (International/Toll) and ask for the Celsion Corporation Third Quarter 2014 Conference Call (Conference Code: 3981708) to register ten minutes before the call is scheduled to begin. The call will also be broadcast live on the internet at http://www.celsion.com.
CLSN: 2.41 (+0.09)
Celsion Presents Preclinical Data for its TheraSilence(TM) Platform at the miRNA World Conference Workshop on miRNA Delivery
PR Newswire - Wed Oct 29, 7:00AM CDT
Celsion Corporation (NASDAQ: CLSN) today announced the presentation of data related to TheraSilence(TM), the Company's lung-specific RNA delivery technology, at the miRNA World Conference Workshop on miRNA Delivery in Boston, MA. The data was presented by Dr. Khursheed Anwer, Celsion's Executive Vice President and Chief Scientific Officer, during a panel presentation, and highlighted formulation characteristics of the TheraSilence delivery platform, preclinical proof-of concept data and data supportive of GEN-2 (formerly referred to as EGEN-002), Celsion's RNA interference (RNAi) therapeutic for the treatment of lung cancer. Celsion acquired the TheraSilence platform and GEN-2 through its acquisition of EGEN, Inc. in June 2014.
CLSN: 2.41 (+0.09)
Celsion Announces Appointment of Michael H. Tardugno to Executive Chairman of the Board of Directors
PR Newswire - Tue Oct 07, 4:00PM CDT
Celsion Corporation (NASDAQ: CLSN) announced that the Board of Directors has appointed Michael H. Tardugno, the Company's President and CEO, to the additional position of Executive Chairman of the Board. Mr. Tardugno's appointment is consistent with the Board's previously established succession plan and follows the passing of Max E. Link, Ph.D. which was announced earlier today. At the direction of Mr. Tardugno, the Nominating Committee of the Board of Directors has begun the process to identify qualified candidates to fill the vacancy on the Company's Board.
CLSN: 2.41 (+0.09), ABT: 46.09 (+0.87), BMY: 60.04 (+0.56)
Celsion Announces The Unexpected Passing of Max E. Link, Ph.D., Chairman of the Board
PR Newswire - Tue Oct 07, 3:35PM CDT
Celsion Corporation (NASDAQ: CLSN) is saddened to announce the passing of Max E. Link, Ph.D., a Director and the Chairman of the Board of Directors of the Company. Dr. Link passed away unexpectedly at the age of 74.
CLSN: 2.41 (+0.09)
INVESTOR ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Celsion Corp. Regarding Possible Breaches of Fiduciary Duty
PR Newswire - Wed Sep 17, 1:18PM CDT
Levi & Korsinsky, LLP is investigating Celsion Corp. (NasdaqCM: CLSN) in connection with possible claims of breaches of fiduciary duty by the board of directors of the Company.
CLSN: 2.41 (+0.09)
